Capecitabine (BioDeep_00000002401)

   

human metabolite blood metabolite


代谢物信息卡片


pentyl N-{1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl}carbamate

化学式: C15H22FN3O6 (359.1492564)
中文名称: 卡培他滨
谱图信息: 最多检出来源 Homo sapiens(blood) 1.04%

分子结构信息

SMILES: CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O
InChI: InChI=1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1

描述信息

Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01B - Antimetabolites > L01BC - Pyrimidine analogues
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite
CONFIDENCE standard compound; EAWAG_UCHEM_ID 2845
D009676 - Noxae > D000963 - Antimetabolites
D000970 - Antineoplastic Agents
Capecitabine is an oral proagent that is converted to its active metabolite, 5-FU, by thymidine phosphorylase.

同义名列表

29 个代谢物同义名

pentyl N-{1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl}carbamate; (1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester; (1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester; (1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester; (1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester; (1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester; Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid; (1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester; Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid; Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid; Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid; Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate; Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid; Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid; Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate; Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate; Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate; Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate; Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate; 5-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine; N(4)-Pentyloxycarbonyl-5-deoxy-5-fluorocytidine; Capecitabine-d11; Capecitabinum; Capecitabina; Capecitabine; Capecitabin; Ro 09-1978; Xeloda; R340



数据库引用编号

26 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

4 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(2)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(2)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Fanming Kong, Lu Zhao, Na Wang, Dou Zhang, Ziwei Wang, Qingyun Mei, Yongchao Yu, Yingjie Jia. The FJQR Has Synergistic Effect with Fluoropyrimidine in the Maintenance Treatment for HER-2 Negative Gastric Cancer. Recent patents on anti-cancer drug discovery. 2024; 19(2):165-175. doi: 10.2174/1574892818666230522161742. [PMID: 38214356]
  • Tianqun Lang, Runqi Zhu, Xiao Zhu, Wenlu Yan, Yu Li, Yihui Zhai, Ting Wu, Xin Huang, Qi Yin, Yaping Li. Combining gut microbiota modulation and chemotherapy by capecitabine-loaded prebiotic nanoparticle improves colorectal cancer therapy. Nature communications. 2023 08; 14(1):4746. doi: 10.1038/s41467-023-40439-y. [PMID: 37550297]
  • Hao Wang, Zheng-Lu Wang, Sai Zhang, De-Jun Kong, Rui-Ning Yang, Lei Cao, Jian-Xi Wang, Sei Yoshida, Zhuo-Lun Song, Tao Liu, Shun-Li Fan, Jia-Shu Ren, Jiang-Hong Li, Zhong-Yang Shen, Hong Zheng. Metronomic capecitabine inhibits liver transplant rejection in rats by triggering recipients' T cell ferroptosis. World journal of gastroenterology. 2023 May; 29(20):3084-3102. doi: 10.3748/wjg.v29.i20.3084. [PMID: 37346150]
  • Wei-Jian Mei, Xiao-Zhong Wang, Yun-Feng Li, Yue-Ming Sun, Chun-Kang Yang, Jun-Zhong Lin, Zu-Guang Wu, Rui Zhang, Wei Wang, Yong Li, Ye-Zhong Zhuang, Jian Lei, Xiang-Bin Wan, Ying-Kun Ren, Yong Cheng, Wen-Liang Li, Zi-Qiang Wang, Dong-Bo Xu, Xian-Wei Mo, Hai-Xing Ju, Sheng-Wei Ye, Jing-Lin Zhao, Hong Zhang, Yuan-Hong Gao, Zhi-Fan Zeng, Wei-Wei Xiao, Xiao-Peng Zhang, Xuan Zhang, E Xie, Yi-Fei Feng, Jing-Hua Tang, Xiao-Jun Wu, Gong Chen, Li-Ren Li, Zhen-Hai Lu, De-Sen Wan, Jin-Xin Bei, Zhi-Zhong Pan, Pei-Rong Ding. Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Initial Results of a Phase III Trial. Annals of surgery. 2023 04; 277(4):557-564. doi: 10.1097/sla.0000000000005780. [PMID: 36538627]
  • Jia-Ming Wu, Ao Zhang, Yu Dong, Si-Hong Lin, Jin-Cheng Meng, Can-Tu Fang. Colorectal cancer with testicular metastasis: A case report and literature review. Medicine. 2023 Mar; 102(11):e33214. doi: 10.1097/md.0000000000033214. [PMID: 36930122]
  • Hui-Zhong Jiang, Ya-Li Jiang, Bing Yang, Feng-Xi Long, Zhu Yang, Dong-Xin Tang. Traditional Chinese medicines and capecitabine-based chemotherapy for colorectal cancer treatment: A meta-analysis. Cancer medicine. 2023 01; 12(1):236-255. doi: 10.1002/cam4.4896. [PMID: 35650714]
  • Ye Yuan, Xumei Liu, Yi Cai, Wenyuan Li. Pyrotinib versus lapatinib therapy for HER2 positive metastatic breast cancer patients after first-line treatment failure: A meta-analysis and systematic review. PloS one. 2023; 18(1):e0279775. doi: 10.1371/journal.pone.0279775. [PMID: 36602979]
  • Zhipeng Wang, Hanglin Li, Yunlei Yun, Hongsen Wang, Bosu Meng, Yuhui Mu, Shouhong Gao, Xia Tao, Wansheng Chen. A dynamic multiple reaction monitoring strategy to develop and optimize targeted metabolomics methods: Analyzing bile acids in capecitabine-induced diarrhea. Journal of pharmaceutical and biomedical analysis. 2022 Sep; 219(?):114938. doi: 10.1016/j.jpba.2022.114938. [PMID: 35850015]
  • Mei Liu, Huiying Fang, Shengqiang Qian. Adjuvant capecitabine for early triple-negative breast cancer: A meta-analysis of randomized controlled trials. Asian journal of surgery. 2022 09; 45(9):1748-1750. doi: 10.1016/j.asjsur.2022.01.039. [PMID: 35168861]
  • Matthew Ng, Sylvia Chen, Whee Sze Ong, Akhila Balachander, Amanda Seet, Joe Yeong, Natalia Sutiman, Tony Kiat Hon Lim, Bernett Lee, Yu Amanda Guo, Wai Fook Leong, Sze Sing Lee, Justina Lam, Su Pin Choo, Anders Jacobsen Skanderup, Subhra Kumar Biswas, David Tai, Balram Chowbay. A phase 1b study of OXIRI in pancreatic adenocarcinoma patients and its immunomodulatory effects. International journal of cancer. 2022 08; 151(3):435-449. doi: 10.1002/ijc.34021. [PMID: 35415893]
  • Majed Alrobaian, Sagar Suman Panda, Waleed H Almalki, Obaid Afzal, Imran Kazmi, Manal A Alossaimi, Fahad A Al-Abbasi, Hanadi A Katouah, Rehan A Rub, B V V Ravi Kumar, Mahfoozur Rahman, Sarwar Beg. Development and Validation of Chemometrics-Assisted Green UPLC-MS/MS Bioanalytical Method for Simultaneous Estimation of Capecitabine and Lapatinib in Rat Plasma. Journal of chromatographic science. 2022 Jul; 60(6):559-570. doi: 10.1093/chromsci/bmab094. [PMID: 34318311]
  • Y Fang, S Wang, Q Yang, S You, X Xing. [Chaihu Guizhi Decoction plus or minus formula combined with capecitabine inhibits IL-6/STAT3 signaling to suppress triple-negative breast cancer xenografts in nude mice]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University. 2022 Jun; 42(6):905-912. doi: 10.12122/j.issn.1673-4254.2022.06.15. [PMID: 35790442]
  • Gunnar Folprecht, Anke Reinacher-Schick, Jürgen Weitz, Celine Lugnier, Anna-Lena Kraeft, Sarah Wisser, Daniela E Aust, Lukas Weiss, Nikolas von Bubnoff, Michael Kramer, Christian Thiede, Andrea Tannapfel. The CIRCULATE Trial: Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation (AIO-KRK-0217). Clinical colorectal cancer. 2022 06; 21(2):170-174. doi: 10.1016/j.clcc.2021.09.005. [PMID: 34772609]
  • Wenyue Zhou, Lu Ni, Manxi Luo, Xinyao Shu, Peng Cao, Meng Qiu. Rare capecitabine-induced acute hypertriglyceridemia with angina: a case report and review of the literature. Annals of palliative medicine. 2022 Jun; 11(6):2152-2156. doi: 10.21037/apm-21-1109. [PMID: 34498471]
  • Sepideh Elyasi, Sara Rasta, Ali Taghizadeh-Kermani, Sare Hosseini. Topical henna and curcumin (Alpha®) ointment efficacy for prevention of capecitabine induced hand-foot syndrome: A randomized, triple-blinded, placebo-controlled clinical. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences. 2022 Jun; 30(1):117-125. doi: 10.1007/s40199-022-00438-8. [PMID: 35320555]
  • Shuhei Sakai, Shinji Kobuchi, Yukako Ito, Toshiyuki Sakaeda. Assessment of Drug-drug Interaction and Optimization in Capecitabine and Irinotecan Combination Regimen using a Physiologically Based Pharmacokinetic Model. Journal of pharmaceutical sciences. 2022 05; 111(5):1522-1530. doi: 10.1016/j.xphs.2021.12.021. [PMID: 34965386]
  • Hikari Araki, Toru Takenaka, Koichi Takahashi, Fumiaki Yamashita, Kazuaki Matsuoka, Kunihiro Yoshisue, Ichiro Ieiri. A semimechanistic population pharmacokinetic and pharmacodynamic model incorporating autoinduction for the dose justification of TAS-114. CPT: pharmacometrics & systems pharmacology. 2022 05; 11(5):604-615. doi: 10.1002/psp4.12747. [PMID: 34951129]
  • Qiaoling Yang, Chuping Chen, Jianmin Ran. Capecitabine-induced severe diabetes and hypokalemia: a case report. Journal of medical case reports. 2022 Apr; 16(1):163. doi: 10.1186/s13256-022-03392-w. [PMID: 35462530]
  • Veerle Casneuf, Ivan Borbath, Marc Van den Eynde, Yolanda Verheezen, Wim Demey, Alain G Verstraete, Kathleen Bm Claes, Vincent Haufroid, Karen P Geboes. Joint Belgian recommendation on screening for DPD-deficiency in patients treated with 5-FU, capecitabine (and tegafur). Acta clinica Belgica. 2022 Apr; 77(2):346-352. doi: 10.1080/17843286.2020.1870855. [PMID: 33423619]
  • Feng Ye, Lei Bian, Jiahuai Wen, Ping Yu, Na Li, Xiaoming Xie, Xi Wang. Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: a new era? A meta-analysis of randomized controlled trials. BMC cancer. 2022 Mar; 22(1):261. doi: 10.1186/s12885-022-09326-5. [PMID: 35279130]
  • Leni van Doorn, Niels Heersche, Femke M de Man, Peter de Bruijn, Ivo Bijl, Esther Oomen-de Hoop, Ferry A L M Eskens, Ate van der Gaast, Ron H J Mathijssen, Sander Bins. Effect of the Proton Pump Inhibitor Esomeprazole on the Systemic Exposure of Capecitabine: Results of A Randomized Crossover Trial. Clinical pharmacology and therapeutics. 2022 02; 111(2):455-460. doi: 10.1002/cpt.2444. [PMID: 34656072]
  • Satoru Mitsuboshi, Takahiro Niimura, Masaki Yoshino, Yoshika Sakamoto, Yoshito Zamami, Keisuke Ishizawa. Fluoropyridmidine use and hypertriglyceridemia among Japanese patients: analysis of adverse event database. International journal of clinical pharmacy. 2022 Feb; 44(1):260-263. doi: 10.1007/s11096-021-01324-0. [PMID: 34482500]
  • Mirjana Radovanovic, Jennifer J Schneider, Mohsen Shafiei, Jennifer H Martin, Peter Galettis. Measurement of 5- fluorouracil, capecitabine and its metabolite concentrations in blood using volumetric absorptive microsampling technology and LC-MS/MS. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2022 Jan; 1188(?):123075. doi: 10.1016/j.jchromb.2021.123075. [PMID: 34891049]
  • Carolina Cerrella Cano, Eduardo Junquera Alonso, Marina Terroba Alonso, Francisco Xavier Cano Calderero, Lucía Seoane Blanco, Edisa M Armesto González. Capecitabine-induced hyperammonemic encephalopathy. Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva. 2022 Jan; 114(1):56. doi: 10.17235/reed.2021.8129/2021. [PMID: 34154371]
  • Wenen Zhou, Xueying Su, Lusheng Sun, Yanjun Liu, Zhenzhen Wang, Xiaoyu Wang, Yanhong Yang. Efficacy and safety of bevacizumab combined with chemotherapy in the treatment of advanced colorectal cancer and the effect on its adverse reactions. Pakistan journal of pharmaceutical sciences. 2022 Jan; 35(1(Special)):381-386. doi: . [PMID: 35236652]
  • Milad Rahimpour, Ghorbangol Ashabi, Ahmad Mustafa Rahimi, Shahnaz Halimi, Mahshid Panahi, Mahdi Alemrajabi, Fatemeh Nabavizadeh. Lactobacillus rhamnosus R0011 Treatment Enhanced Efficacy of Capecitabine against Colon Cancer in Male Balb/c Mice. Nutrition and cancer. 2022; 74(7):2622-2631. doi: 10.1080/01635581.2021.2014901. [PMID: 34918611]
  • Qingqian Zhang, Yue Qian, Ying Yin. Comparison of S-1-based vs. capecitabine-based adjuvant chemotherapy for patients with gastric cancer: a systematic review and meta-analysis. European journal of clinical pharmacology. 2021 Dec; 77(12):1791-1804. doi: 10.1007/s00228-021-03187-w. [PMID: 34275019]
  • Chen-Jing Wang, Ting Li, Ping-Ping Lin, Ye Tao, Xin Jiang, Xin Li, Qing Wen, Yu Cao. Pharmacokinetic and Safety Comparison of Two Capecitabine Tablets in Patients with Colorectal or Breast Cancer Under Fed Conditions: A Multicenter, Randomized, Open-Label, Three-Period, and Reference-Replicated Crossover Study. Advances in therapy. 2021 09; 38(9):4798-4814. doi: 10.1007/s12325-021-01817-4. [PMID: 34347254]
  • Laura Molenaar-Kuijsten, Bart Albertus Wilhelmus Jacobs, Sophie Alberdine Kurk, Anne Maria May, Thomas Petrus Catharina Dorlo, Jacob Hendrik Beijnen, Neeltje Steeghs, Alwin Dagmar Redmar Huitema. Worse capecitabine treatment outcome in patients with a low skeletal muscle mass is not explained by altered pharmacokinetics. Cancer medicine. 2021 07; 10(14):4781-4789. doi: 10.1002/cam4.4038. [PMID: 34121365]
  • Huahua Zhang, Yandong Zhang, Chaonan Huang, Jiangfeng Wang. Cost-effectiveness Analysis of Trastuzumab Emtansine as Second-line Therapy for HER2-Positive Breast Cancer in China. Clinical drug investigation. 2021 Jun; 41(6):569-577. doi: 10.1007/s40261-021-01035-4. [PMID: 33876415]
  • Xiong Yun, Hua Meng, Anfu Zhou, Jingchao Jia, Weiling Qian. Efficacy of transcatheter arterial chemoembolization combined with capecitabine and cetuximab in the treatment of colorectal cancer with liver metastasis. Journal of B.U.ON. : official journal of the Balkan Union of Oncology. 2021 May; 26(3):1002-1008. doi: . [PMID: 34268965]
  • Kathryn E Burns, Ottiniel Chavani, Soo Hee Jeong, John A Duley, David Porter, Michael Findlay, R Matthew Strother, Nuala A Helsby. Comparison of a thymine challenge test and endogenous uracil-dihydrouracil levels for assessment of fluoropyrimidine toxicity risk. Cancer chemotherapy and pharmacology. 2021 05; 87(5):711-716. doi: 10.1007/s00280-021-04240-2. [PMID: 33687515]
  • Federico DI Staso, Irene Gattazzo, Beatrice Taurelli Salimbeni, Alessandro Lambiase, Gianluca Scuderi, Silvio DI Staso, Marco Ciancaglini. Treatment of Capecitabine Corneal Side Effects With Autologous Blood-derived Serum Eye Drops. In vivo (Athens, Greece). 2021 May; 35(3):1881-1884. doi: 10.21873/invivo.12451. [PMID: 33910876]
  • Binghe Xu, Min Yan, Fei Ma, Xichun Hu, Jifeng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Yuanting Gu, Qianjun Chen, Jinping Liu, Jing Cheng, Cuizhi Geng, Shukui Qin, Shusen Wang, Jinsong Lu, Kunwei Shen, Qiang Liu, Xiaojia Wang, Hong Wang, Ting Luo, Jin Yang, Yudong Wu, Zhiyong Yu, Xiaoyu Zhu, Chunxia Chen, Jianjun Zou. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. The Lancet. Oncology. 2021 03; 22(3):351-360. doi: 10.1016/s1470-2045(20)30702-6. [PMID: 33581774]
  • Chun A Changou, Her-Shyong Shiah, Li-Tzong Chen, Servina Liu, Frank Luh, Shwu-Huey Liu, Yung-Chi Cheng, Yun Yen. A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma. The oncologist. 2021 03; 26(3):e367-e373. doi: 10.1002/onco.13582. [PMID: 33140457]
  • Marina Sáez-Belló, Víctor Mangas-Sanjuán, Mª Amparo Martínez-Gómez, Mª Ángeles López-Montenegro Soria, Mónica Climente-Martí, Matilde Merino-Sanjuán. Evaluation of ABC gene polymorphisms on the pharmacokinetics and pharmacodynamics of capecitabine in colorectal patients: Implications for dosing recommendations. British journal of clinical pharmacology. 2021 03; 87(3):905-915. doi: 10.1111/bcp.14441. [PMID: 32559325]
  • Shuhei Sakai, Shinji Kobuchi, Yukako Ito, Toshiyuki Sakaeda. A Physiologically Based Pharmacokinetic-Pharmacodynamic Model for Capecitabine in Colorectal Cancer Rats: Simulation of Antitumor Efficacy at Various Administration Schedules. European journal of drug metabolism and pharmacokinetics. 2021 Mar; 46(2):301-315. doi: 10.1007/s13318-021-00674-4. [PMID: 33606175]
  • Y Tian, Q Wang, J Wang, X Y Qiao, J Zhang, Y C Lin, Y Li, L Q Fan, P G Yang, Q Zhao. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial]. Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery. 2021 Feb; 24(2):128-137. doi: 10.3760/cma.j.cn.441530-20201019-00565. [PMID: 33508918]
  • B W Xie, L Zang, J J Ma, J Sun, X Yang, M L Wang, A G Lu, W G Hu, M H Zheng. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer]. Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery. 2021 Feb; 24(2):138-144. doi: 10.3760/cma.j.cn.441530-20200721-00433. [PMID: 33508919]
  • Nastja Lunar, Marie-Christine Etienne-Grimaldi, Pauline Macaire, Fabienne Thomas, Florence Dalenc, Jean-Marc Ferrero, Xavier Pivot, Gérard Milano, Bernard Royer, Antonin Schmitt. Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients. Cancer chemotherapy and pharmacology. 2021 02; 87(2):229-239. doi: 10.1007/s00280-020-04208-8. [PMID: 33386926]
  • Frances Willenbrock, Catrin M Cox, Eileen E Parkes, Charlotte S Wilhelm-Benartzi, Aswin G Abraham, Robert Owens, Ahmad Sabbagh, Christopher M Jones, Daniel L I Hughes, Tim Maughan, Christopher N Hurt, Eric E O'Neill, Somnath Mukherjee. Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer. British journal of cancer. 2021 02; 124(3):581-586. doi: 10.1038/s41416-020-01120-z. [PMID: 33100327]
  • Xiangdong Cheng, Dan Wu, Nong Xu, Luchuan Chen, Zhilong Yan, Ping Chen, Lei Zhou, Jianfa Yu, Jiuwei Cui, Wei Li, Chang Wang, Wenming Feng, Yunhai Wei, Pengfei Yu, Yian Du, Jieer Ying, Zhiyuan Xu, Litao Yang, Yunli Zhang. Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol. BMC cancer. 2021 Jan; 21(1):56. doi: 10.1186/s12885-020-07772-7. [PMID: 33435909]
  • Julie M Janssen, Bart A W Jacobs, Jeroen Roosendaal, Ellen J B Derissen, Serena Marchetti, Jos H Beijnen, Alwin D R Huitema, Thomas P C Dorlo. Population Pharmacokinetics of Intracellular 5-Fluorouridine 5'-Triphosphate and its Relationship with Hand-and-Foot Syndrome in Patients Treated with Capecitabine. The AAPS journal. 2021 01; 23(1):23. doi: 10.1208/s12248-020-00533-1. [PMID: 33417061]
  • Xi Wang, Shu-Sen Wang, Heng Huang, Li Cai, Li Zhao, Rou-Jun Peng, Ying Lin, Jun Tang, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Fei Xu, Xi-Wen Bi, Jia-Jia Huang, Ji-Bin Li, Dan-Mei Pang, Cong Xue, Yan-Xia Shi, Zhen-Yu He, Huan-Xin Lin, Xin An, Wen Xia, Ye Cao, Ying Guo, Yan-Hong Su, Xin Hua, Xin-Yue Wang, Ruo-Xi Hong, Kui-Kui Jiang, Chen-Ge Song, Zhang-Zan Huang, Wei Shi, Yong-Yi Zhong, Zhong-Yu Yuan. Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial. JAMA. 2021 01; 325(1):50-58. doi: 10.1001/jama.2020.23370. [PMID: 33300950]
  • Sulai Liu, Zhendong Zhong, Weimin Yi, Zhangtao Yu, Zhihua Zhang, Guoyi Xia, Bo Jiang, Yinghui Song, Chuang Peng. Effect of Hyperthermic Intraperitoneal Perfusion Chemotherapy Combined with Radical Surgery and Capecitabine on Stage III Gallbladder Cancer. Canadian journal of gastroenterology & hepatology. 2021; 2021(?):4006786. doi: 10.1155/2021/4006786. [PMID: 34660468]
  • Daxin Huang, Qingliang Lin, Jianyuan Song, Benhua Xu. Prognostic Value of Pretreatment Serum CA199 in Patients with Locally Advanced Rectal Cancer Treated with CRT Followed by TME with Normal Pretreatment Carcinoembryonic Antigen Levels. Digestive surgery. 2021; 38(1):24-29. doi: 10.1159/000508442. [PMID: 33171467]
  • Umaira Rehman, Rai Muhammad Sarfraz, Asif Mahmood, Zahid Hussain, Hnin Ei Thu, Nadiah Zafar, Muhammad Umar Ashraf, Nighat Batool. Smart pH-responsive Co-polymeric Hydrogels for Controlled Delivery of Capecitabine: Fabrication, Optimization and In Vivo Toxicology Screening. Current drug delivery. 2021; 18(9):1256-1271. doi: 10.2174/1567201818666210212085912. [PMID: 33583374]
  • Xinjie Zhang, Haitao Chen, Yi Lu, Chao Xu, Wang Yao, Lu Xu, Runzhe Zhang, Liping Zhang, Qinghua Yao. Prevention of oxaliplatin-related neurotoxicity by ω-3 PUFAs: A double-blind randomized study of patients receiving oxaliplatin combined with capecitabine for colon cancer. Medicine. 2020 Dec; 99(50):e23564. doi: 10.1097/md.0000000000023564. [PMID: 33327312]
  • Takahiro Inaishi, Ken-Ichi Fujita, Natsumi Matsumoto, Tomoya Shimokata, Osamu Maeda, Toyone Kikumori, Norifumi Hattori, Goro Nakayama, Yuichi Ando. Correlation Between the Metabolic Conversion of a Capecitabine Metabolite, 5'-Deoxy-5-fluorocytidine, and Creatinine Clearance. In vivo (Athens, Greece). 2020 Nov; 34(6):3539-3544. doi: 10.21873/invivo.12196. [PMID: 33144465]
  • Fang-Fang Yuan, Rong-Rong Zhang, Xiaoli Ma, Jian Yang, Yan-Ping Huang, Zhao-Sheng Liu. Cooperation effect of 4-vinylbenzeneboronic acid/methacrylic acid on affinity of capecitabine imprinted polymer for drug carrier. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2020 Nov; 154(?):105476. doi: 10.1016/j.ejps.2020.105476. [PMID: 32717430]
  • Alessandro Di Federico, Giacomo Nuvola, Monia Sisi, Barbara Lenzi, Elisabetta Nobili, Davide Campana. Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible?. Anti-cancer drugs. 2020 11; 31(10):1103-1105. doi: 10.1097/cad.0000000000000987. [PMID: 32826413]
  • Nilgun Yildirim, Mahir Cengiz. Predictive clinical factors of chronic peripheral neuropathy induced by oxaliplatin. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2020 Oct; 28(10):4781-4788. doi: 10.1007/s00520-020-05319-x. [PMID: 31974772]
  • Ashok Varma, Mathaiyan Jayanthi, Biswajit Dubashi, Deepak Gopal Shewade, Rajan Sundaram. Genetic influence of DPYD*9A polymorphism on plasma levels of 5-fluorouracil and subsequent toxicity after oral administration of capecitabine in colorectal cancer patients of South Indian origin. Drug metabolism and personalized therapy. 2020 09; 35(4):. doi: 10.1515/dmpt-2020-0133. [PMID: 32966231]
  • S J Schraa, K L van Rooijen, D E W van der Kruijssen, C Rubio Alarcón, J Phallen, M Sausen, J Simmons, V M H Coupé, W M U van Grevenstein, S Elias, H M Verkooijen, M M Laclé, L J W Bosch, D van den Broek, G A Meijer, V E Velculescu, R J A Fijneman, G R Vink, M Koopman. Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study. BMC cancer. 2020 Aug; 20(1):790. doi: 10.1186/s12885-020-07252-y. [PMID: 32819390]
  • Alberto Bongiovanni, Chiara Liverani, Sara Pusceddu, Silvana Leo, Giovanni Di Meglio, Stefano Tamberi, Daniele Santini, Fabio Gelsomino, Francesca Pucci, Rossana Berardi, Ivan Lolli, Francesca Bergamo, Sergio Ricci, Flavia Foca, Stefano Severi, Toni Ibrahim. Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol. BMJ open. 2020 07; 10(7):e034393. doi: 10.1136/bmjopen-2019-034393. [PMID: 32690499]
  • Clémence Marin, Anis Krache, Chloé Palmaro, Mathilde Lucas, Valentin Hilaire, Renée Ugdonne, Bénédicte De Victor, Sylvie Quaranta, Caroline Solas, Bruno Lacarelle, Joseph Ciccolini. A Simple and Rapid UPLC-UV Method for Detecting DPD Deficiency in Patients With Cancer. Clinical and translational science. 2020 07; 13(4):761-768. doi: 10.1111/cts.12762. [PMID: 32058656]
  • Xandra García-González, Bartosz Kaczmarczyk, Judith Abarca-Zabalía, Fabienne Thomas, Pilar García-Alfonso, Luis Robles, Vanessa Pachón, Ángeles Vaz, Sara Salvador-Martín, María Sanjurjo-Sáez, Luis A López-Fernández. New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine. Cancer chemotherapy and pharmacology. 2020 07; 86(1):45-54. doi: 10.1007/s00280-020-04093-1. [PMID: 32529295]
  • Salahaddin Hajizadeh, Khalil Farhadi, Rahim Molaei, Mehrdad Forough. Silver nanoparticles-tragacanth gel as a green membrane for effective extraction and determination of capecitabine. Journal of separation science. 2020 Jul; 43(13):2666-2674. doi: 10.1002/jssc.202000251. [PMID: 32275113]
  • Jiali Dai, Yuetong Chen, Cuiju Tang, Xiaowei Wei, Yang Gong, Jingsun Wei, Dongying Gu, Jinfei Chen. Pyrotinib in the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: A case report. Medicine. 2020 Jun; 99(25):e20809. doi: 10.1097/md.0000000000020809. [PMID: 32569228]
  • Radu Vidra, Raluca Bodea, Voicu Mercea, Adina Nemes. Challenges of pancreatic cancer chemotherapy in the COVID-19 era. Journal of gastrointestinal and liver diseases : JGLD. 2020 06; 29(2):273-275. doi: 10.15403/jgld-2527. [PMID: 32531001]
  • Saeedeh Ansari, Saeed Masoum. Ultrasound-assisted dispersive solid-phase microextraction of capecitabine by multi-stimuli responsive molecularly imprinted polymer modified with chitosan nanoparticles followed by HPLC analysis. Mikrochimica acta. 2020 06; 187(6):366. doi: 10.1007/s00604-020-04345-0. [PMID: 32494864]
  • Noha Rashad, Thoraya Abdelhamid, Samia A Shouman, Hanan Nassar, Mervat A Omran, Eman D El Desouky, Hussein Khaled. Capecitabine-Based Chemoendocrine Combination as First-Line Treatment for Metastatic Hormone-Positive Metastatic Breast Cancer: Phase 2 Study. Clinical breast cancer. 2020 06; 20(3):228-237. doi: 10.1016/j.clbc.2019.12.012. [PMID: 32005499]
  • Natsumi Matsumoto, Yutaro Kubota, Hiroo Ishida, Masae Sekido, Ryotaro Ohkuma, Tomoyuki Ishiguro, Yuya Hirasawa, Hirotsugu Ariizumi, Takuya Tsunoda, Toshikazu Ikusue, Kouji Kobayashi, Atsushi Hisamatsu, Hirokazu Toshima, Ken Shimada, Ken-Ichi Fujita. Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients. Cancer chemotherapy and pharmacology. 2020 06; 85(6):1119-1128. doi: 10.1007/s00280-020-04087-z. [PMID: 32458030]
  • L Sun, Y Xu, T Zhang, Y Yang. Impact of the COVID-19 outbreak on adjuvant chemotherapy for patients with stage II or III colon cancer: experiences from a multicentre clinical trial in China. Current oncology (Toronto, Ont.). 2020 06; 27(3):159-162. doi: 10.3747/co.27.6529. [PMID: 32669926]
  • Junjie Li, Keda Yu, Da Pang, Changqin Wang, Jun Jiang, Suisheng Yang, Yunjiang Liu, Peifen Fu, Yuan Sheng, Guojun Zhang, Yali Cao, Qi He, Shude Cui, Xijing Wang, Guosheng Ren, Xinzheng Li, Shiyou Yu, Pengxi Liu, Xiang Qu, Jinhai Tang, Ouchen Wang, Zhimin Fan, Guoqin Jiang, Jin Zhang, Jiandong Wang, Hongwei Zhang, Shui Wang, Jianguo Zhang, Feng Jin, Nanyan Rao, Binlin Ma, Pingqing He, Binghe Xu, Zhigang Zhuang, Jianfeng Wang, Qiang Sun, Xiaofeng Guo, Miao Mo, Zhimin Shao. Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 06; 38(16):1774-1784. doi: 10.1200/jco.19.02474. [PMID: 32275467]
  • Jeroen Roosendaal, Bart A W Jacobs, Dick Pluim, Hilde Rosing, Niels de Vries, Erik van Werkhoven, Bastiaan Nuijen, Jos H Beijnen, Alwin D R Huitema, Jan H M Schellens, Serena Marchetti. Phase I pharmacological study of continuous chronomodulated capecitabine treatment. Pharmaceutical research. 2020 May; 37(5):89. doi: 10.1007/s11095-020-02828-6. [PMID: 32382808]
  • Shuhei Sakai, Shinji Kobuchi, Yukako Ito, Toshiyuki Sakaeda. Assessment of pharmacokinetic variations of capecitabine after multiple administration in rats: a physiologically based pharmacokinetic model. Cancer chemotherapy and pharmacology. 2020 05; 85(5):869-880. doi: 10.1007/s00280-020-04057-5. [PMID: 32240335]
  • Jean-Luc Raoul, Julien Edeline, Marine Gilabert, Hélène Senellart, Jean-Sébastien Frenel. [Proton pump inhibitors and cancers: A hazardous association?]. Bulletin du cancer. 2020 Apr; 107(4):458-464. doi: 10.1016/j.bulcan.2019.12.009. [PMID: 32057465]
  • Kazuteru Watanabe, Atsushi Ishibe, Jun Watanabe, Mitsuyoshi Ota, Shoichi Fujii, Yasushi Ichikawa, Mari S Oba, Itaru Endo. The effect of TJ-28 (Eppikajutsuto) on the prevention of hand-foot syndrome using Capecitabine for colorectal cancer: The Yokohama Clinical Oncology Group Study (YCOG1102). Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology. 2020 04; 39(2):204-210. doi: 10.1007/s12664-020-01039-6. [PMID: 32406009]
  • Tiphaine Robin, Franck Saint-Marcoux, Doriane Toinon, Naïma Tafzi, Pierre Marquet, Souleiman El Balkhi. Automatic quantification of uracil and dihydrouracil in plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2020 Apr; 1142(?):122038. doi: 10.1016/j.jchromb.2020.122038. [PMID: 32169798]
  • Lars H Jensen, Rikke Fredslund Andersen, Lene Byriel, Eva Fernebro, Anders Jakobsen, Jan Lindebjerg, Lise Nottelmann, John Ploen, Torben F Hansen. Phase II study of gemcitabine, oxaliplatin and capecitabine in patients with KRAS exon 2 mutated biliary tract cancers. Acta oncologica (Stockholm, Sweden). 2020 Mar; 59(3):298-301. doi: 10.1080/0284186x.2019.1701201. [PMID: 31838939]
  • Kentaro Yamazaki, Shigemi Matsumoto, Chiyo K Imamura, Chiemi Yamagiwa, Ayaka Shimizu, Takayuki Yoshino. Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study. Japanese journal of clinical oncology. 2020 Feb; 50(2):122-128. doi: 10.1093/jjco/hyz149. [PMID: 31665356]
  • Yoichiro Yoshida, Yasuhiro Hashimoto, Makoto Miyazaki, Naoya Aisu, Teppei Yamada, Ryuji Kajitani, Taro Munechika, Yoshiko Matsumoto, Hideki Nagano, Hideki Shimaoka, Akira Komono, Ryohei Sakamoto, Gumpei Yoshimatsu, Fumihiro Yoshimura, Fumiaki Kiyomi, Suguru Hasegawa. 5-Nitrouracil stabilizes the plasma concentration values of 5-FU in colorectal cancer patients receiving capecitabine. Scientific reports. 2020 02; 10(1):2711. doi: 10.1038/s41598-020-59648-2. [PMID: 32066801]
  • Jia Gang Han, Zhen Jun Wang, Wei Gen Zeng, Yan Bin Wang, Guang Hui Wei, Zhi Wei Zhai, Bao Cheng Zhao, Bing Qiang Yi. Efficacy and safety of self-expanding metallic stent placement followed by neoadjuvant chemotherapy and scheduled surgery for treatment of obstructing left-sided colonic cancer. BMC cancer. 2020 Jan; 20(1):57. doi: 10.1186/s12885-020-6560-x. [PMID: 31992260]
  • Penghua Li, Haiqing He, Yunqin Zhang, Rui Yang, Lili Xu, Zixi Chen, Yingying Huang, Limei Bao, Guozhi Xiao. Glycosyl ortho-(1-phenylvinyl)benzoates versatile glycosyl donors for highly efficient synthesis of both O-glycosides and nucleosides. Nature communications. 2020 01; 11(1):405. doi: 10.1038/s41467-020-14295-z. [PMID: 31964883]
  • Sonali G Thorat, Rupesh V Chikhale, Madhukar R Tajne. Development and Validation of HPLC and HPTLC Methods for Therapeutic Drug Monitoring of Capecitabine in Colorectal Cancer Patients. Journal of chromatographic science. 2020 Jan; 57(10):892-900. doi: 10.1093/chromsci/bmz067. [PMID: 31609432]
  • Ran Yu, Xuefeng Wu, Liqun Jia, Yanni Lou. Effect of Chinese Herbal Compound LC09 on Patients With Capecitabine-Associated Hand-Foot Syndrome: A Randomized, Double-Blind, and Parallel-Controlled Trial. Integrative cancer therapies. 2020 Jan; 19(?):1534735420928466. doi: 10.1177/1534735420928466. [PMID: 32597691]
  • Matilda Holm, Emma Andersson, Emerik Osterlund, Ali Ovissi, Leena-Maija Soveri, Anna-Kaisa Anttonen, Soili Kytölä, Kristiina Aittomäki, Pia Osterlund, Ari Ristimäki. Detection of KRAS mutations in liquid biopsies from metastatic colorectal cancer patients using droplet digital PCR, Idylla, and next generation sequencing. PloS one. 2020; 15(11):e0239819. doi: 10.1371/journal.pone.0239819. [PMID: 33237900]
  • Xue-Song Sun, Sai-Lan Liu, Yu-Jing Liang, Qiu-Yan Chen, Xiao-Yun Li, Lin-Quan Tang, Hai-Qiang Mai. The role of capecitabine as maintenance therapy in de novo metastatic nasopharyngeal carcinoma: A propensity score matching study. Cancer communications (London, England). 2020 01; 40(1):32-42. doi: 10.1002/cac2.12004. [PMID: 32112522]
  • Nuala A Helsby, John Duley, Kathryn E Burns, Claire Bonnet, Soo Hee Jeong, Elliott Brenman, Paula Barlow, Katrina Sharples, David Porter, Michael Findlay. A case-control study to assess the ability of the thymine challenge test to predict patients with severe to life threatening fluoropyrimidine-induced gastrointestinal toxicity. British journal of clinical pharmacology. 2020 01; 86(1):155-164. doi: 10.1111/bcp.14153. [PMID: 31658382]
  • Jacqueline Ramírez, Larry K House, Theodore G Karrison, Linda A Janisch, Michelle Turcich, Ravi Salgia, Mark J Ratain, Manish R Sharma. Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib. Journal of clinical pharmacology. 2019 12; 59(12):1632-1640. doi: 10.1002/jcph.1476. [PMID: 31274208]
  • Roberto Aquilani, Silvia Brugnatelli, Maurizia Dossena, Roberto Maestri, Sara Delfanti, Daniela Buonocore, Federica Boschi, Elena Simeti, Anna Maria Condino, Manuela Verri. Oxaliplatin-Fluoropyrimidine Combination (XELOX) Therapy Does Not Affect Plasma Amino Acid Levels and Plasma Markers of Oxidative Stress in Colorectal Cancer Surgery Patients: A Pilot Study. Nutrients. 2019 Nov; 11(11):. doi: 10.3390/nu11112667. [PMID: 31694176]
  • Mansi Upadhyay, Sandeep Kumar Reddy Adena, Harsh Vardhan, Sarita K Yadav, Brahmeshwar Mishra. Locust bean gum and sodium alginate based interpenetrating polymeric network microbeads encapsulating Capecitabine: Improved pharmacokinetics, cytotoxicity &in vivo antitumor activity. Materials science & engineering. C, Materials for biological applications. 2019 Nov; 104(?):109958. doi: 10.1016/j.msec.2019.109958. [PMID: 31500043]
  • C X Lu, B W Zheng, B Bai, J L Hu, S F Fan, D F Shang, D Yang, C L Zhao, S D Cang. [Effect of omeprazole on plasma concentration and adverse reactions of capecitabine in patients with colon cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology]. 2019 Sep; 41(9):708-711. doi: 10.3760/cma.j.issn.0253-3766.2019.09.012. [PMID: 31550863]
  • Cheng Kong, Renyuan Gao, Xuebing Yan, Linsheng Huang, Jide He, Hao Li, Jie You, Huanlong Qin. Alterations in intestinal microbiota of colorectal cancer patients receiving radical surgery combined with adjuvant CapeOx therapy. Science China. Life sciences. 2019 Sep; 62(9):1178-1193. doi: 10.1007/s11427-018-9456-x. [PMID: 30796721]
  • S Fatemeh Mousavi, Mohammad Hossein Fatemi. Probing the binding mechanism of capecitabine to human serum albumin using spectrometric methods, molecular modeling, and chemometrics approach. Bioorganic chemistry. 2019 09; 90(?):103037. doi: 10.1016/j.bioorg.2019.103037. [PMID: 31212179]
  • Crescent C Gbeto, Sylvie Quaranta, Roxane Mari, Raphaelle Fanciullino, Catherine Roche, Sophie Nahon, Caroline Solas, L'Houcine Ouafik, Bruno Lacarelle, Thierry Allegre, Joseph Ciccolini. Lethal toxicities after capecitabine intake in a previously 5-FU-treated patient: why dose matters with dihydropryimidine dehydrogenase deficiency. Pharmacogenomics. 2019 08; 20(13):931-938. doi: 10.2217/pgs-2019-0028. [PMID: 31486738]
  • Radka Obermannova, Dalibor Valik, Dirk Hasenclever, Lenka Zdrazilova-Dubska, Ulrich Hacker, Regina Demlova, Iveta Selingerova, Florian Lordick. High prevalence of severe hypovitaminosis D in patients with advanced gastric cancer treated with first-line chemotherapy with or without anti-EGFR-directed monoclonal antibody (EXPAND trial) showing no prognostic impact. European journal of cancer (Oxford, England : 1990). 2019 07; 116(?):107-113. doi: 10.1016/j.ejca.2019.05.011. [PMID: 31195354]
  • Masae Sekido, Ken-Ichi Fujita, Yutaro Kubota, Hiroo Ishida, Takehiro Takahashi, Ryotaro Ohkuma, Takuya Tsunoda, Fumihiro Ishikawa, Motoko Shibanuma, Yasutsuna Sasaki. Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, and 5-fluorouracil. Cancer chemotherapy and pharmacology. 2019 06; 83(6):1127-1135. doi: 10.1007/s00280-019-03837-y. [PMID: 30972456]
  • Gilbert Chu, Julia Salzman. Hyperammonemia after capecitabine associated with occult impairment of the urea cycle. Cancer medicine. 2019 05; 8(5):1996-2004. doi: 10.1002/cam4.2036. [PMID: 30977266]
  • G L Ouyang, W J Meng, P Shu, X B Deng, B Wu, D Jiang, H Zhuang, Y L Shen, Z G Zhou, Z Q Wang, X Wang. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors]. Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery. 2019 Apr; 22(4):349-356. doi: 10.3760/cma.j.issn.1671-0274.2019.04.007. [PMID: 31054549]
  • Wen Wee Ma, Hao Xie, Gerald Fetterly, Laura Pitzonka, Amy Whitworth, Charles LeVea, John Wilton, Krystin Mantione, Sarah Schihl, Grace K Dy, Patrick Boland, Renuka Iyer, Wei Tan, William Brady, Robert M Straubinger, Alex A Adjei. A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients. American journal of clinical oncology. 2019 02; 42(2):184-189. doi: 10.1097/coc.0000000000000492. [PMID: 30418178]
  • Amar M Eltweri, Anne L Thomas, Wen Y Chung, Bruno Morgan, John Thompson, Ashley R Dennison, David J Bowrey. The Effect of Supplementary Omegaven® on the Clinical Outcome of Patients With Advanced Esophagogastric Adenocarcinoma Receiving Palliative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy: A Phase II clinical trial. Anticancer research. 2019 Feb; 39(2):853-861. doi: 10.21873/anticanres.13185. [PMID: 30711967]
  • Shinji Kobuchi, Mako Akutagawa, Yukako Ito, Toshiyuki Sakaeda. Association between the pharmacokinetics of capecitabine and the plasma dihydrouracil to uracil ratio in rat: A surrogate biomarker for dihydropyrimidine dehydrogenase activity. Biopharmaceutics & drug disposition. 2019 Jan; 40(1):44-48. doi: 10.1002/bdd.2168. [PMID: 30592773]
  • Tao Peng, Yulu Ouyang, Kanger Tong. Rechallenge capecitabine after fluoropyrimidine-induced cardiotoxicity in rectal cancer: A case report. Medicine. 2019 Jan; 98(2):e14057. doi: 10.1097/md.0000000000014057. [PMID: 30633206]
  • Antonio Cubillo, Rafael Álvarez-Gallego, Manuel Muñoz, Gregory Pond, Sofía Perea, Gema Sánchez, María Martin, Jesús Rodríguez-Pascual, Elena Garralda, Estela Vega, Emilio de Vicente, Yolanda Quijano, César Muñoz, Lisardo Ugidos, Rodrigo A Toledo, Manuel Hidalgo. Dynamic Angiogenic Switch as Predictor of Response to Chemotherapy-Bevacizumab in Patients With Metastatic Colorectal Cancer. American journal of clinical oncology. 2019 01; 42(1):56-59. doi: 10.1097/coc.0000000000000474. [PMID: 29975196]
  • Bing Yang, Chun-Shui Pan, Quan Li, Zhu Yang, Feng-Xi Long, Jing-Yu Fan, Chuan-She Wang, Jing-Yan Han, Dong-Xin Tang. Inhibitory effects of Chanling Gao on the proliferation and liver metastasis of transplanted colorectal cancer in nude mice. PloS one. 2019; 14(2):e0201504. doi: 10.1371/journal.pone.0201504. [PMID: 30789971]
  • Stephen L Chan, Anthony W H Chan, Frankie Mo, Brigette B Y Ma, Kenneth C W Wong, Daisy Lam, Florence S T Mok, Anthony T C Chan, Tony Mok, K C Allen Chan. Association Between Serum Folate Level and Toxicity of Capecitabine During Treatment for Colorectal Cancer. The oncologist. 2018 12; 23(12):1436-1445. doi: 10.1634/theoncologist.2017-0637. [PMID: 29802221]
  • Cristina Sottani, Elena Grignani, Laura Zaratin, Donatella Santorelli, Emanuele Studioso, Davide Lonati, Carlo A Locatelli, Ornella Pastoris, Sara Negri, Danilo Cottica. A new, sensitive and versatile assay for quantitative determination of α-fluoro-β-alanine (AFBA) in human urine by using the reversed-phase ultrahigh performance-tandem mass spectrometry (rp-UHPLC-MS/MS) system. Toxicology letters. 2018 Dec; 298(?):164-170. doi: 10.1016/j.toxlet.2018.10.007. [PMID: 30315949]